Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitis
- PMID: 39395423
- DOI: 10.1016/S1473-3099(24)00600-5
Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitis
Conflict of interest statement
SF received grants or contracts from Moderna and MSD; consulting fees from GlaxoSmithKline, AstraZeneca, MSD, Pfizer, Cepheid, and Moderna; payment or honoraria from GlaxoSmithKline, AstraZeneca, MSD, Pfizer, Cepheid, and Moderna; and support for attending meetings or travel from AstraZeneca, Pfizer, Cepheid, and Moderna. All other authors declare no competing interests.
LinkOut - more resources
Full Text Sources